Pfizer And BioNTech Start Late-stage Study Of COVID-19 Vaccine Candidate

(RTTNews) - Pfizer Inc. (PFE) and BioNTech (BNTX) said that they have started a global Phase 2/3 clinical study to evaluate a single nucleoside-modified messenger RNA or modRNA candidate from their BNT162 mRNA-based vaccine program against SARS-CoV-2.

The study is expected to include about 120 sites globally except china and could include up to 30,000 participants.

The companies said they have chosen to advance their BNT162b2 vaccine candidate into the Phase 2/3 study, at a 30 g dose level in a 2 dose regimen. BNT162b2, which recently received U.S. Food and Drug Administration Fast Track designation, encodes an optimized SARS-CoV-2 full length spike glycoprotein, which is the target of virus neutralizing antibodies.

"The initiation of the Phase 2/3 trial is a major step forward in our progress toward providing a potential vaccine to help fight the ongoing COVID-19 pandemic, and we look forward to generating additional data as the program progresses," said Kathrin Jansen, Senior Vice President and Head of Vaccine Research & Development, Pfizer.

The companies plan to manufacture globally up to 100 million doses of vaccine candidate by the end of 2020 and potentially more than 1.3 billion doses by the end of 2021.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Latest Markets Videos


Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Learn More